Some companies are already offering new and cheaper ways to make photocatalies, but there are still plenty of other competitors to consider.The world's most common materials are already making their way into products in different forms.There's a growing demand for photocatalkys that can be used in a variety of applications.A recent report from McKinsey & Company estimated that there will be mo...
Google News headline Merck and Pfizer agree to share ‘most sensitive data’ article Merck: “Merck and our pharmaceutical partners are working together on a collaborative project to share most sensitive data and other information that will be most useful to our team.”
Pfizer: “We are pleased to conclude this agreement with Pfizer and share most of the most sensitive information and other relevant data that will help us better understand the impact of the pandemic on the U.S. market.”
USTR: “These agreements reflect the shared understanding of the importance of maintaining the highest levels of quality and security of information in our business to protect our customers and keep patients and the broader public safe.”
Source: Google News article Google has agreed to share data on patients with Merck “at the highest level possible” as part of the company’s deal to buy the biotechnology company, USTR announced Tuesday.
The USTR said Merck would share the “most sensitive” data with the Pfizer pharmaceutical unit and other US regulators as well as the FBI and the Department of Justice.
“We understand and respect the importance that patient safety is of the utmost importance to us,” USTR Chief Executive Officer Julie Byerly said in a statement.
“While we remain fully committed to continuing our partnership with Pfiznich, this agreement demonstrates our confidence in our ability to continue to provide the most reliable and comprehensive medical care to patients around the world.”
Pfizner and Merck announced the deal in a joint statement that said the agreement would be the “largest data-sharing agreement in the history of Pfizer.”
“This will provide us with unprecedented insight into the pandemics impact on our customers, suppliers and suppliers of healthcare providers,” Pfizners statement said.
The deal comes after Pfiz’s $5 billion acquisition of the biopharmaceutical company on Sept. 1.